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Abstract
Background: Acute lymphoblastic leukemia is a rare hematological malignancy. Pure subdural hemorrhages in a
patient with acute lymphoblastic leukemia patient are extremely rare.
Case presentation: This case presented acute spontaneous subdural hemorrhage without head trauma at first, and
acute lymphoblastic leukemia was diagnosed later. The second time, the patient was admitted with multiple pure
subdural hemorrhages in different locations and periods with a history of slight head trauma.
Conclusions: Pure subdural hemorrhages can occur in a patient with acute lymphoblastic leukemia. More care
would be needed for pure subdural hemorrhages without obvious head trauma, and patients with hematological
malignancies should be protected from even mild head trauma.
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Background
Leukemia, especially acute types, can lead to intracranial
hemorrhage (ICH) with high morbidity and mortality [1, 2].
Chen CY et al. reported that ICH occurred in 2.8 % adult
patients with hematological malignancies [3]. But the main
type of ICH was intraparenchymal hemorrhage, accounted
for 74.5 % [4]. Acute lymphoblastic leukemia (ALL) rarely
resulted in pure subdural hemorrhage (SDH). This is the
first report about several pure SDHs which included two
acute types, separately without and with head trauma, and
one chronic type in a patient with ALL according to previ-
ous literature reports.
Case presentation
A 63-year-old female who denied any history of head
trauma was referred to our hospital with a 2-day slight
headache and low-grade fever. She was conscious, and ini-
tial physical examination was normal without traumatic
clinical manifestations. She denied other histories of
diseases but hypertension. Brain computed tomography
(CT) disclosed acute pure SDH of left frontal-temporal
side (Fig. 1).
On the second day, the laboratory data were found abnor-
mal, which included leukocyte count (21.1 × 109/L), plate-
let count (36.0 × 109/L), lymphocyte count (15.7 × 109/L),
D-Dimer (2.91 mg/L), and the positive plasma protamine
paracoagulation test (3P test). Her blood coagulation test
was normal. We requested a consultation of hematologist,
who performed a bone marrow aspiration. The result sug-
gested that the sum of abnormal lymphocyte accounted for
about 61.0 % (Fig. 2). The diagnosis of ALL was revealed
for active hyperplasia of bone marrow tissues, diffuse small
lymphocyte and suppressed hyperplasia of granulocytes
series, erythroid series and megakaryocyte series.
As hematoma absorbed (Fig. 3) and hypertension con-
trolled, our hematologists enacted a treatment plan for
her, but her family rejected and took her to some Shanghai
hospital. According to follow-up care, we knew that she
underwent a chemotherapy in Shanghai and went back
home in a very feeble condition.
About 1 month after her first discharge, she was re-
ferred to our hospital again for slight headache with a
history of mild head trauma. CT suggested two left
SDHs in different locations and periods (Fig. 4). The
chronic one was a recurrent kind of hematoma and had
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Fig. 1 CT suggested acute pure SDH of left frontal-temporal side in the first hospitalization
Fig. 2 Pathological analysis of bone marrow suggested increasing abnormal lymphocyte cells
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a relationship with her first acute SDH which had been
absorbed completely.
Leukocyte count (153.9 × 109/L), platelet count (6.0 ×
109/L), lymphocyte count (20.0 × 109/L), D-Dimer
(6.98 mg/L), and erythrocyte count (1.97 × 1012/L) re-
vealed aggravated condition. Fecal occult blood was
positive with (+). The blood coagulation test was nor-
mal again. In addition to the symptomatic treatments,
we advised specialized therapy of department of
hematology, but her families rejected again. 1 month
later, the patient died of multiple organ dysfunction
syndrome (MODS) after long-term unconsciousness.
Discussion
This case had repeated SDHs. The first one was acute
and spontaneous without definite history of head
trauma. The second time, she had two SDHs in different
locations, which included an acute type and an unaware
chronic type. These were all pure SDHs, which was very
rare. In the study of Chen CY [3], the incidence of pure
Fig. 4 CT suggested two left SDHs in different locations and periods in the second hospitalization
Fig. 3 CT suggested absorbed SDH when the patient was discharged from hospital for the first time. a CT suggested absorbed SDH of left
frontal-temporal side in the first hospitalization. b CT suggested absorbed SDH of left parietal side in the first hospitalization
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SDH was 0.47 % in patients with hematological malig-
nancies. But repeated pure SDHs in ALL were never
reported.
For tearing of the bridging and cortical veins, SDH
could occur. Acute SDH often has a clear history of
head trauma. Chronic SDH usually occurs after 3 weeks
or even a longer time so that the history of head trauma
may be forgotten. But in the patients with hematological
malignancies, head trauma may be not a necessary
cause, which was also proved through our case.
The possible risk factors of ICH caused by leukemia
include thrombocytopenia, platelet dysfunction, dissemi-
nated intravascular coagulation (DIC), coagulation factor
deficiency, hyperleukocytosis, vessel wall abnormalities,
hypertension and sepsis [2, 4]. Our patient had
thrombocytopenia all the time. ALL was getting worse
that could be found in her laboratory data. The D-Dimer
was getting higher, 3P tests were positive and fecal oc-
cult blood was positive with (+), which all revealed ag-
gravated DIC.
Yhim HY et al. reported bilateral chronic subdural
hemorrhage as a serious adverse event of dasatinib in a
patient with Philadelphia chromosome-positive acute
lymphoblastic leukemia [5]. Our patient had no chance
of chromosome examination, but the clinical manifesta-
tions of her first acute SDH and the second chronic
SDH were similar to that case. This may suggest the
evolution of SDH in ALL patients even without dasati-
nib, that acute SDH in ALL may have a strong tendency
to develop chronic SDH.
This patient had repeated SDHs without serious cen-
tral nervous system involvement or surgery. This did
not mean insignificant condition. Previous study had
shown high mortality (50 %) among SDH patients with
hematological malignancies [5]. Each SDH, caused by
hematological malignancy, may be also associated with
a higher possibility of neurosurgery and potential ad-
verse outcomes.
So far, there is still no effective way to prevent ICH,
including SDH, in patients with hematological malig-
nancies. Prophylactic platelet transfusions to maintain
the platelet count at a safe threshold has been proved to
be an effective treatment to decreased the risk of
hemorrhagic complication with hematological malig-
nancies [6]. Considering the etiology of SDH, ALL pa-
tients should also be protected from even mild head
trauma through our case.
Conclusion
Various types of pure SDHs in a patient with ALL are
extremely rare. Acute pure SDH can occur in ALL pa-
tients without definite head trauma. Even if acute SDH
was absorbed completely, secondary unaware chronic
SDH could occur. Homonymous acute SDH and chronic
SDH in different locations could coexist in ALL.
Hematological malignancies should be considered when
a patient, who had no obvious history of head trauma,
came with acute SDH and low-grade fever. With the ag-
gravation of ALL, worse laboratory data may suggest
higher risk of chronic SDH after acute SDH. In addition
to active diagnosis and treatment, ALL patients should
be protected from even mild head trauma to avoid SDH
for their tendency of hemorrhage.
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